Alnylam shares reach historic high after breakthrough for RNAi therapeutics

2 November 2017

Massachusetts, USA-based Alnylam Pharmaceuticals (Nasdaq: ALNY) is presenting detailed data from its Phase III APOLLO study into patisiran at the European ATTR Amyloidosis Meeting in Paris.

The company’s share price, which was already riding high after topline results, revealed in September, showed the candidate had met its primary and secondary endpoints, is already up more than 15% on the news.

Patisiran is an experimental therapy that targets the hereditary form of ATTR amyloidosis, a rare and severe disease in which abnormal proteins accrete in the body.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK